Short Interest in AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) Expands By 661.7%

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) saw a large increase in short interest in December. As of December 31st, there was short interest totaling 205,893 shares, an increase of 661.7% from the December 15th total of 27,032 shares. Based on an average daily volume of 243,723 shares, the short-interest ratio is presently 0.8 days. Currently, 7.2% of the shares of the stock are short sold. Currently, 7.2% of the shares of the stock are short sold. Based on an average daily volume of 243,723 shares, the short-interest ratio is presently 0.8 days.

AIM ImmunoTech Price Performance

NYSEAMERICAN AIM traded down $0.01 during trading hours on Wednesday, reaching $1.27. The company’s stock had a trading volume of 28,618 shares, compared to its average volume of 73,773. The firm has a fifty day simple moving average of $1.40 and a 200-day simple moving average of $3.09. AIM ImmunoTech has a 52 week low of $1.07 and a 52 week high of $36.00. The stock has a market cap of $3.61 million, a P/E ratio of -0.06 and a beta of 1.21.

AIM ImmunoTech (NYSEAMERICAN:AIM) last posted its earnings results on Monday, November 17th. The company reported ($1.57) earnings per share for the quarter. The business had revenue of $0.03 million for the quarter. On average, research analysts expect that AIM ImmunoTech will post -0.3 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of AIM ImmunoTech from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 8th. Two investment analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat, the company currently has an average rating of “Strong Buy”.

Hedge Funds Weigh In On AIM ImmunoTech

An institutional investor recently bought a new position in AIM ImmunoTech stock. Corient Private Wealth LLC purchased a new position in AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 10,001 shares of the company’s stock, valued at approximately $87,000. Corient Private Wealth LLC owned 0.37% of AIM ImmunoTech as of its most recent filing with the Securities and Exchange Commission. 12.02% of the stock is currently owned by hedge funds and other institutional investors.

About AIM ImmunoTech

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.